Fiduciary Trust Co reduced its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 19.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 23,730 shares of the medical instruments supplier's stock after selling 5,579 shares during the quarter. Fiduciary Trust Co's holdings in Becton, Dickinson and Company were worth $5,384,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also made changes to their positions in the company. Principal Financial Group Inc. boosted its stake in Becton, Dickinson and Company by 1.5% in the 3rd quarter. Principal Financial Group Inc. now owns 1,179,715 shares of the medical instruments supplier's stock worth $284,429,000 after purchasing an additional 16,918 shares during the period. ORG Partners LLC increased its stake in Becton, Dickinson and Company by 689.4% in the fourth quarter. ORG Partners LLC now owns 3,205 shares of the medical instruments supplier's stock valued at $727,000 after acquiring an additional 2,799 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in Becton, Dickinson and Company by 1.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 45,434 shares of the medical instruments supplier's stock valued at $10,954,000 after purchasing an additional 797 shares in the last quarter. Hilltop National Bank lifted its position in Becton, Dickinson and Company by 6.9% during the 4th quarter. Hilltop National Bank now owns 1,658 shares of the medical instruments supplier's stock valued at $376,000 after purchasing an additional 107 shares during the period. Finally, Ridgewood Investments LLC boosted its stake in Becton, Dickinson and Company by 14.3% during the 4th quarter. Ridgewood Investments LLC now owns 2,160 shares of the medical instruments supplier's stock worth $490,000 after acquiring an additional 270 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.
Becton, Dickinson and Company Stock Performance
BDX traded down $0.02 during trading on Tuesday, hitting $175.32. 3,772,504 shares of the company traded hands, compared to its average volume of 1,879,814. The firm has a market cap of $50.25 billion, a P/E ratio of 29.12, a price-to-earnings-growth ratio of 1.63 and a beta of 0.31. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The stock's fifty day moving average is $207.87 and its 200 day moving average is $222.48. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. The firm had revenue of $5.27 billion for the quarter, compared to analysts' expectations of $5.35 billion. During the same period in the prior year, the firm earned $3.17 EPS. The company's revenue was up 4.5% compared to the same quarter last year. As a group, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 9th will be paid a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.37%. The ex-dividend date of this dividend is Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio is currently 79.39%.
Becton, Dickinson and Company declared that its board has approved a share repurchase program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company's management believes its shares are undervalued.
Analyst Ratings Changes
A number of research firms have recently issued reports on BDX. Barclays cut their price objective on Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating for the company in a research report on Monday, April 7th. Raymond James lowered Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Friday, May 2nd. Wells Fargo & Company lowered shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research report on Thursday, May 1st. Stifel Nicolaus decreased their price objective on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Finally, The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 target price for the company. in a research report on Friday, May 2nd. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $231.44.
Check Out Our Latest Stock Report on Becton, Dickinson and Company
Insider Activity at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 700 shares of the firm's stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $227.99, for a total value of $159,593.00. Following the sale, the director now directly owns 36,033 shares in the company, valued at $8,215,163.67. This trade represents a 1.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Richard Byrd sold 1,940 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $224.91, for a total value of $436,325.40. Following the sale, the executive vice president now owns 7,411 shares in the company, valued at approximately $1,666,808.01. This trade represents a 20.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,578 shares of company stock worth $795,986. Insiders own 0.36% of the company's stock.
Becton, Dickinson and Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Further Reading
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
